BioProcess Insider Covers Gallant’s $18M Raise and Manufacturing Expansion
July 9, 2025 12:00 PM ET
BioProcess Insider spotlighted Gallant’s $18 million Series B funding and the company’s advancement toward large-scale manufacturing of allogeneic stem cell therapies for pets.
From BioProcess Insider
Gallant secures $18M for veterinary allogeneic therapy production
Gallant is redefining veterinary medicine with ready-to-use stem cell therapies that reduce inflammation, restore function, and fit seamlessly into everyday practice.